Evolving technology for drug delivery system in cardiovascular surgery

Research output: Contribution to journalArticlepeer-review


There have been variable evolving technologies for drug delivery system (DDS) applied in cardiovascular surgery. Enormous clinical success with drug eluting stent enhanced cardiac surgical researchers to expand the concept of local delivery of effective agents. Representative agents introduced for those technologies include basic fibroblast growth factor(bFGF) and antibiotics, especially vancomycin. With these agents, numerous attempts have been made to treat peripheral tissue ischemia, intractable graft infection, catheter-related infection and to enhance sternal healing process via angiogenesis. Interim results from in vitro and in vivo experiments are promising. Above all, bFGF slow-release system has already launched in clinical arena, and has yielded some therapeutic effect in the treatment of critical limb ischemia. In terms of the DDS application for infection control, antibiotic-loaded polymethylmethacrylate beads for the treatment of extracavitary prosthetic vascular graft infections have been utilized in Western countries. In this country, gelatin-coated biodegradable polyglycolic acid with bFGF has been tested for the patients undergoing aortic aneurysmal repair to prevent pseudoaneurysmal formation in long term occurring at the aortic anastomotic site.

Original languageEnglish
Pages (from-to)289-295
Number of pages7
JournalDrug Delivery System
Issue number4
Publication statusPublished - 2012


  • Angiogenesis
  • Antibiotics
  • Cardiovascular system
  • Drug delivery system
  • obFGF

ASJC Scopus subject areas

  • Pharmaceutical Science


Dive into the research topics of 'Evolving technology for drug delivery system in cardiovascular surgery'. Together they form a unique fingerprint.

Cite this